

TIKOSYN[®] (dofetilide)

Follow the 3 steps in the T.I.P.S.[™] (Tikosyn In Pharmacy System) program

1. ENROLL

- Your pharmacy must be enrolled in the T.I.P.S. program to order, stock, and dispense Tikosyn.
- To confirm your enrollment, call 1-877-TIKOSYN (1-877-845-6796) or visit www.tikosynlist.com.

2. ORDER

- Order Tikosyn through your wholesaler.
- Tikosyn orders faxed by your wholesaler are processed during normal Pfizer Customer Service business hours - Monday through Friday 7:00 AM to 6:00 PM Central Standard Time.

Pfizer will verify pharmacy enrollment and drop ship Tikosyn to the pharmacy.

Note: Due to importance of adherence to Tikosyn therapy once initiated, we recommend you maintain an inventory of Tikosyn on hand to meet immediate patient needs, especially over week-ends or holidays.

3. DISPENSE

- On receipt of a prescription, confirm that the prescriber is a participant in the Tikosyn Education Distribution[™] program by calling the IVR (Interactive Voice Response) at 1-800-788-7353 or visiting www.tikosynlist.com.
- After verification, stamp the back of the prescription with the T.I.P.S. stamp and write in your initials and the date.
- File the prescription.
- If you cannot verify that the prescriber has participated in the Tikosyn Education Distribution[™] program, call 1-877-TIKOSYN (1-877-845-6796) to speak with a Tikosyn Customer Representative.

See T.I.P.S. program procedures booklet for complete guidelines. If you have questions about Tikosyn or T.I.P.S. program procedures, please call 1-877-TIKOSYN (1-877-845-6796) or visit www.tikosyn.com.

TIKOSYN is indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm.

To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education.



TIKOSYN[®] 500
250
125
mg
capsules

INCHES

9

8

7

6

5

4

3

2

1

TIKOSYN[®] PHARMACIST SAFETY INFORMATION

Tikosyn is indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. The most serious side effect is torsades de pointes and the most common side effects are headache, chest pain, and dizziness. Please see full prescribing information provided.

TIKOSYN[®] (dofetilide) is contraindicated with verapamil, with hydrochlorothiazide (alone or in combinations such as with triamterene), and with cation transport inhibitors such as cimetidine, ketoconazole, trimethoprim (alone or in combination with sulfamethoxazole), prochlorperazine, and megestrol. (Alternatives to cimetidine include Maalox[®], Prilosec[®], and Zantac[®].)

Warnings/Interactions: Inhibitors of the CYP3A4, renal cation transports, drugs that prolong the QT interval, and other antiarrhythmics may increase the risk of proarrhythmia either by increasing dofetilide exposure or by adding to its QT-prolonging effect.

Precautions/Interactions: The following should be coadministered with care as they might increase dofetilide levels: macrolide antibiotics, azole antifungal agents, protease inhibitors, selective serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, nefazodone, zafirlukast, norfloxacin, quinine, triamterene, metformin, amiloride, and grapefruit juice.

Maalox is a registered trademark of Novartis Consumer Health, Inc. Prilosec is a registered trademark of AstraZeneca LP. Zantac is a registered trademark of GlaxoSmithKline.

TIKOSYN[®]
(dofetilide)
500
250
125
mg
capsules

